A total of 415 patients were assigned to cemiplimab (209) or placebo (206). The median follow-up was 24 months. Cemiplimab was superior to placebo with respect to disease-free survival (24 vs. 65 ...

Does the combination of avelumab plus IgG1 monoclonal antibody cetuximab improve progression-free survival (PFS) compared with avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC). The ...

Shlomo Koyfman, MD, discusses the MK-3475-630/ KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer. Shlomo Koyfman, MD, a radiation oncologist at Cleveland ...

BROOKLYN HEIGHTS — Overheard in line at one of most popular pastry outlets on Montague Street: "Hope I can get them into a camp ..." A mother with two pre-schoolers in tow was showing a friend ...

Libtayo (cemiplimab), approved as treatment for advanced cases of squamous cell carcinoma of the skin, might soon have a role in the treatment of local cases of the disease. Results of a phase 3 trial ...